Home LiteratureArticle Details
PMID: 20525911 Published · ppublish English Editorial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

The Journal of clinical endocrinology and metabolism ·Vol. 95 ·No. 6 ·2010-06-00 ·Pages 2621-4

Fagin JA, Tuttle RM, Pfister DG

Abstract

暂无摘要

MeSH Terms
Adenocarcinoma, Follicular/drug therapy,genetics,pathology Antineoplastic Agents/adverse effects,therapeutic use Benzenesulfonates/therapeutic use Biomarkers, Tumor Carcinoma, Medullary/drug therapy,genetics,pathology Carcinoma, Papillary/drug therapy,genetics,pathology Humans Indoles/adverse effects,therapeutic use Neoplasm Metastasis/prevention & control Niacinamide/analogs & derivatives Phenylurea Compounds Protein Kinase Inhibitors/adverse effects,therapeutic use Pyridines/therapeutic use Pyrroles/adverse effects,therapeutic use Sorafenib Sunitinib Thyroid Neoplasms/drug therapy,genetics,pathology
Chemicals
Antineoplastic Agents Benzenesulfonates Biomarkers, Tumor Indoles Phenylurea Compounds Protein Kinase Inhibitors Pyridines Pyrroles Niacinamide Sorafenib Sunitinib
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Fagin James A
Tuttle R Michael
Pfister David G
References (28)
28 references, click to expand
  1. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    J Clin Oncol. 2010 Feb 10;28(5):767-72 PMID: 20065189
  2. Targeting the RET pathway in thyroid cancer.
    Clin Cancer Res. 2009 Dec 1;15(23):7119-23 PMID: 19934298
  3. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
    BJU Int. 2010 May;105(9):1247-54 PMID: 19863525
  4. Phase II trial of sorafenib in metastatic thyroid cancer.
    J Clin Oncol. 2009 Apr 1;27(10):1675-84 PMID: 19255327
  5. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71 PMID: 20371662
  6. Motesanib diphosphate in progressive differentiated thyroid cancer.
    N Engl J Med. 2008 Jul 3;359(1):31-42 PMID: 18596272
  7. Receptor tyrosine kinase inhibitors in thyroid cancer.
    Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1023-38 PMID: 19041829
  8. Array of cutaneous adverse effects associated with sorafenib.
    J Am Acad Dermatol. 2009 Aug;61(2):360-1 PMID: 19615549
  9. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    J Clin Oncol. 2009 Aug 10;27(23):3794-801 PMID: 19564535
  10. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
    Eur J Endocrinol. 2009 Dec;161(6):923-31 PMID: 19773371
  11. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Mol Cancer Ther. 2008 Oct;7(10):3129-40 PMID: 18852116
  12. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Cancer Res. 2007 Jul 15;67(14):6956-64 PMID: 17638907
  13. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
    Br J Cancer. 2006 Sep 4;95(5):581-6 PMID: 16880785
  14. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
    Cancer Res. 2002 Dec 15;62(24):7284-90 PMID: 12499271
  15. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
    J Chemother. 2004 Nov;16 Suppl 4:49-51 PMID: 15693160
  16. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
    Hum Gene Ther. 2003 Jul 1;14(10):971-82 PMID: 12869215
  17. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
    J Clin Oncol. 2008 Oct 10;26(29):4708-13 PMID: 18541897
  18. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95 PMID: 20392874
  19. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
    J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9 PMID: 16684830
  20. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Nature. 2010 Mar 18;464(7287):427-30 PMID: 20179705
  21. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Cancer Biol Ther. 2008 Apr;7(4):496-501 PMID: 18219225
  22. Refractory thyroid cancer: a paradigm shift in treatment is not far off.
    J Clin Oncol. 2008 Oct 10;26(29):4701-4 PMID: 18541893
  23. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Cancer Res. 2009 Jun 1;69(11):4885-93 PMID: 19487299
  24. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
    J Clin Oncol. 2009 Aug 10;27(23):e59-61 PMID: 19597016
  25. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Nature. 2010 Mar 18;464(7287):431-5 PMID: 20130576
  26. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74 PMID: 17160391
  27. Phase II trial of sorafenib in advanced thyroid cancer.
    J Clin Oncol. 2008 Oct 10;26(29):4714-9 PMID: 18541894
  28. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
    Cancer Res. 2005 May 1;65(9):3538-41 PMID: 15867345
Article Info
Journal
The Journal of clinical endocrinology and metabolism
Abbr.
J Clin Endocrinol Metab
ISSN
1945-7197
DOI
10.1210/jc.2010-0800
Published
2010-06-00
Pages
2621-4
Language
English
Region
United States
NLM ID
0375362
PMCID
PMC2902070
Subset
IM
Grants
NCI NIH HHS · R01 CA050706 · United States
NCI NIH HHS · R01 CA072597 · United States
NCI NIH HHS · CA72597 · United States
NCI NIH HHS · CA50706 · United States
Corrections
CommentOn
PMID: 20371662
CommentOn
PMID: 20392874
External Links
PubMed source DOI: 10.1210/jc.2010-0800 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2